# Mixed Solvent Micelle Formulation Procedure

The equilibrium-nanoprecipitation (ENC) method provides a highly uniform, efficient, and scalable manufacturing process for producing polymer micelle formulations such as lung surfactant therapeutics.

Researchers at Purdue University have developed a new procedure for creating polymer micelle formulations such as polymer lung surfactant therapeutics that are used to treat respiratory distress syndrome (RDS). RDS is a disease of native lung surfactants that causes a severe decrease in blood oxygenation and affects approximately 190,000 patients in the United States each year. Traditional manufacturing methods pose challenges for producing polymer micelles employed in Purdue's efforts to develop an artificial polymer lung surfactant. The equilibrium-nanoprecipitation (ENC) method created by Purdue researchers minimizes variation between batches and pre-treats bulk amphiphilic block copolymers to alleviate mixing nonuniformity. The ENC technique has been tested with three unique batches of RDS therapeutics using dynamic light scattering to verify the composition of each batch.

## Advantages:

- -Uniformity
- -Large-Scale Manufacturing
- -Efficiency

Potential Applications:

- -Pharmaceuticals
- -Nanotechnologies
- -Scientific Research
- -Drug Discovery

### **Technology Validation:**

## **Technology ID**

2020-WON-69093

#### Category

Pharmaceuticals/Drug Discovery & Development Pharmaceuticals/Drug Delivery & Formulations

Pharmaceuticals/Pharmaceutical Manufacturing & Methods

#### **Authors**

Daniel Fesenmeier You-Yeon Won

#### **Further information**

Joe Kasper JRKasper@prf.org

Nathan Smith nesmith@prf.org

#### View online



The compositions and batch consistency for solvent micelle formations produced using the new procedure developed by Purdue researchers have been verified by dynamic light scattering (DLS).

Recent Publication:

"Polymer Lung Surfactants"

American Chemical Society Journal of Applied Bio Materials

DOI: 10.1021/acsabm.8b00061/

**TRL:** 2

## **Intellectual Property:**

Provisional-Patent, 2020-06-02, United States | NATL-Patent, 2021-06-01, Japan | PCT-Patent, 2021-06-01, WO | NATL-Patent, 2021-06-01, Europe | NATL-Patent, 2021-06-01, Canada | NATL-Patent, 2022-11-17, United States

**Keywords:** polymer micelle formulations, polymer lung surfactant therapeutics, respiratory distress syndrome, RDS, equilibriumnanoprecipitation, ENC method, amphiphilic block copolymers, uniformity, large-scale manufacturing, drug discovery